Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06D ANTI-DEMENTIA DRUGS
N06DA Anticholinesterases
N06DA03 Rivastigmine
D02558 Rivastigmine tartrate <US>
USP drug classification [BR:br08302]
Antidementia Agents
Cholinesterase Inhibitors
Rivastigmine
D02558 Rivastigmine tartrate
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG00984 Rivastigmine
D02558 Rivastigmine tartrate
DG01594 Butyrylcholinesterase inhibitor
DG00984 Rivastigmine
D02558 Rivastigmine tartrate
DG01968 Antidementia agent
DG00984 Rivastigmine
D02558 Rivastigmine tartrate
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01968 Antidementia agent
D02558 Rivastigmine tartrate
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Carboxylic-ester hydrolases
ACHE
D02558 Rivastigmine tartrate <US>
BCHE
D02558 Rivastigmine tartrate <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02558
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02558
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02558
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG00984 Rivastigmine
DG01594 Butyrylcholinesterase inhibitor
DG00984 Rivastigmine
DG01968 Antidementia agent
DG00984 Rivastigmine